| Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole (NCT00615914) | Boehringer Ingelheim | 2004-02-01 |
| Special Survey on PD Patients With Renal Dysfunction (NCT00613756) | Boehringer Ingelheim | 2004-02-01 |
| Cell Studies of Parkinson's Disease (NCT00076505) | National Human Genome Research Institute (NHGRI) | 2004-01-14 |
| Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease (NCT02231905) | Boehringer Ingelheim | 2004-01-01 |
| Levetiracetam Treatment of L-dopa Induced Dyskinesias (NCT00076674) | National Institute of Neurological Disorders and Stroke (NINDS) | 2004-01-01 |
| Effects of Deep Brain Stimulation on Motor, Mood, and Cognitive Symptoms in Parkinson's Disease (NCT00360009) | University of Florida | 2004-01-01 |
| Acrylamide and Health Outcomes (NCT06224725) | Karolinska Institutet | 2004-01-01 |
| Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease (NCT00220272) | Sanofi | 2004-01-01 |
| NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485 (NCT00076492) | University of Rochester | 2004-01-01 |
| Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's (NCT00363727) | GlaxoSmithKline | 2003-12-01 |
| Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease (NCT00228150) | Sanofi | 2003-07-01 |
| Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease (NCT00240409) | Boehringer Ingelheim | 2003-07-01 |
| Investigating the Safety of srTMS in the Treatment of Parkinson's Disease (NCT00063284) | National Institute of Neurological Disorders and Stroke (NINDS) | 2003-06-18 |
| Studying Automatic Movements in Patients With Parkinson's Disease (NCT00063661) | National Institute of Neurological Disorders and Stroke (NINDS) | 2003-06-01 |
| Treatment of Depression in Parkinson's Disease Trial (NCT00062738) | Rutgers, The State University of New Jersey | 2003-06-01 |
| Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa (NCT00381472) | GlaxoSmithKline | 2003-06-01 |
| A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) (NCT00148486) | Boehringer Ingelheim | 2003-06-01 |
| Laser Light Visual Cueing for Freezing of Gait in Parkinson's Disease (NCT01502995) | Parkinson's Disease Research, Education, and Clinical Center, Philadelphia | 2003-06-01 |
| Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease (NCT00058838) | Pfizer | 2003-04-01 |
| Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease (NCT00058721) | National Institute of Neurological Disorders and Stroke (NINDS) | 2003-04-01 |
| Transcranial Direct Current Stimulation to Treat Symptoms of Parkinson's Disease (NCT00082342) | National Institute of Neurological Disorders and Stroke (NINDS) | 2003-03-01 |
| A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations (NCT00148512) | Boehringer Ingelheim | 2003-03-01 |
| STEPS Trial - Spheramine Safety and Efficacy Study (NCT00206687) | Bayer | 2003-01-08 |
| Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease (NCT02248207) | Boehringer Ingelheim | 2003-01-01 |
| Weight Changes in Parkinsonian Patients, Treated With Deep Brain Stimulation (NCT00221793) | University Hospital, Bordeaux | 2002-12-01 |
| Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) (NCT00043849) | National Institute on Aging (NIA) | 2002-07-01 |
| How the Loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance (NCT00040196) | National Institute of Neurological Disorders and Stroke (NINDS) | 2002-06-19 |
| JP-1730 to Treat Parkinson's Disease (NCT00040209) | National Institute of Neurological Disorders and Stroke (NINDS) | 2002-06-01 |
| Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164 (NCT00650104) | GlaxoSmithKline | 2002-05-01 |
| The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease (NCT00032812) | National Institute of Neurological Disorders and Stroke (NINDS) | 2002-03-01 |
| Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease (NCT00040404) | Cephalon | 2002-03-01 |
| Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease (NCT02248168) | Boehringer Ingelheim | 2002-03-01 |
| Donepezil to Treat Dementia in Parkinson's Disease (NCT00030979) | National Institute of Neurological Disorders and Stroke (NINDS) | 2002-02-01 |
| Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease (NCT02231255) | Boehringer Ingelheim | 2002-02-01 |
| Study of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease (NCT00029666) | National Institute of Neurological Disorders and Stroke (NINDS) | 2002-01-01 |
| Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease. (NCT00036218) | Pfizer | 2001-12-01 |
| Transcranial Magnetic Stimulation in Parkinson's Disease (NCT00023062) | National Institute of Neurological Disorders and Stroke (NINDS) | 2001-08-01 |
| Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease (NCT00200525) | Mylan Bertek Pharmaceuticals | 2001-07-01 |
| PET Study of the Nicotinic Receptors in Human (NCT00543322) | Commissariat A L'energie Atomique | 2001-07-01 |
| A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients. (NCT00145171) | Mylan Bertek Pharmaceuticals | 2001-02-01 |
| Molecular Epidemiology of Parkinson's Disease (NCT00042107) | National Institute of Environmental Health Sciences (NIEHS) | 2000-09-01 |
| Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease (NCT00036205) | Pfizer | 2000-08-01 |
| The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease (NCT02231294) | Boehringer Ingelheim | 2000-07-01 |
| Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression (NCT00134784) | Institute for Neurodegenerative Disorders | 2000-04-01 |
| Study of LY300164 for the Treatment of Parkinson's Disease (NCT00004576) | National Institute of Neurological Disorders and Stroke (NINDS) | 2000-02-01 |
| Exploring the Comorbidity Between Mental Disorders and General Medical Conditions (NCT03847753) | University of Aarhus | 2000-01-01 |
| GM1 Ganglioside Effects on Parkinson's Disease (NCT00037830) | Thomas Jefferson University | 1999-11-01 |
| Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months (NCT00200512) | Mylan Bertek Pharmaceuticals | 1999-09-01 |
| Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease (NCT00142545) | Mylan Bertek Pharmaceuticals | 1999-07-01 |
| Treatment of Parkinson's Disease With a Transdermal Skin Patch (NCT00001931) | National Institute of Neurological Disorders and Stroke (NINDS) | 1999-05-01 |
| Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease (NCT02172573) | Boehringer Ingelheim | 1999-04-01 |
| Intravenous Levodopa for the Diagnosis of Parkinson's Disease (NCT00001928) | National Institute of Neurological Disorders and Stroke (NINDS) | 1999-03-01 |
| Treatment of Parkinson's Disease With Eliprodil (NCT00001929) | National Institute of Neurological Disorders and Stroke (NINDS) | 1999-03-01 |
| Long-term Administration Study of SND 919 Tablets in Parkinson's Disease (NCT00274131) | Boehringer Ingelheim | 1998-12-01 |
| Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients (NCT02177357) | Boehringer Ingelheim | 1998-11-01 |
| Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease (NCT02248220) | Boehringer Ingelheim | 1998-10-01 |
| Parkinson's Research: The Organized Genetics Initiative (NCT00086073) | Indiana University | 1998-08-01 |
| Randomized Study of Fetal Neurotransplantation for the Treatment of Parkinson's Disease (NCT00004844) | National Institute of Neurological Disorders and Stroke (NINDS) | 1998-07-01 |
| Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease (NCT02233023) | Boehringer Ingelheim | 1998-06-01 |
| Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients (NCT00004451) | National Institute of Mental Health (NIMH) | 1998-03-01 |
| Transcranial Magnetic Stimulation for the Treatment of Parkinson's Disease (NCT00001665) | National Institute of Neurological Disorders and Stroke (NINDS) | 1997-01-01 |
| Phase II Double Blind Controlled Trial of Nigral Grafting in Patients With Parkinson's Disease (NCT00004387) | National Center for Research Resources (NCRR) | 1996-01-01 |
| Study of Axial Mobility Exercises in Parkinson Disease (NCT00004760) | Duke University | 1995-05-01 |
| Embryonic Dopamine Cell Implants for Parkinson's Disease (NCT00038116) | University of Colorado, Denver | 1995-05-01 |
| Genetic Studies of Lysosomal Storage Disorders (NCT00001215) | National Human Genome Research Institute (NHGRI) | 1995-03-08 |
| Double-blind Placebo Surgery Trial for Treatment of Parkinson's Disease (NCT03347955) | University of Denver | 1994-11-01 |
| Phase II Study of Pallidotomy for Parkinson Disease (NCT00004670) | National Center for Research Resources (NCRR) | 1994-10-01 |
| Studies of Frontal Lobe Brain Functioning in Schizophrenia (NCT00001258) | National Institute of Mental Health (NIMH) | 1993-11-26 |
| Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease (NCT00004826) | Memorial Hospital of Rhode Island | 1993-10-01 |
| The French E3N Prospective Cohort Study (NCT03285230) | Institut National de la Santé Et de la Recherche Médicale, France | 1990-06-15 |
| Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study (NCT07522606) | Bial R&D Investments, S.A. | |
| Expanded Access Using Allogeneic Bone-marrow Derived Human Mesenchymal Stem Cells (Allo-hMSC) for a Individual Parkinson's Disease Subject (NCT06798064) | Mya Schiess | |
| Intermediate Size Expanded Access Protocol Using Autologous HB-adMSCs for the Treatment of Parkinson's Disease (NCT06056427) | Hope Biosciences Research Foundation | |
| Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment (NCT00651183) | Boehringer Ingelheim | |
| Telephone Call From Acute Care Physicians to Long Term Care Physicians: Impact on Transitional Care of Elderly Patients (NCT00281749) | Maimonides Medical Center | |
| Compassionate Use Study of Pergolide in Patients With Parkinson's Disease (NCT00624741) | Bausch Health Americas, Inc. | |
| Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease (NCT00006488) | National Center for Research Resources (NCRR) | |
| Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Disease. (NCT04772378) | Hope Biosciences Research Foundation | |
| Chinese Exercise Modalities in Parkinson's Disease (NCT00029809) | National Center for Complementary and Integrative Health (NCCIH) | |
| Expanded Access to Tavapadon (NCT07158827) | AbbVie | |